Skip to content
Peptidepedia

How to Use GHRP-2: Administration, Reconstitution & Storage (2026)

From Peptidepedia, the trusted peptide wiki.

How to Use / Administration Methods

GHRP-2 is administered via subcutaneous injection, typically into the abdominal fat, thigh, or deltoid region.

Injection process:

  1. Reconstitute the lyophilized powder with bacteriostatic water (see Reconstitution section below)
  2. Draw the calculated dose into an insulin syringe (29 to 31 gauge)
  3. Pinch a fold of skin at the injection site
  4. Insert the needle at a 45 to 90 degree angle
  5. Depress the plunger slowly and steadily
  6. Withdraw and dispose of the needle in a sharps container

Injection sites should be rotated to prevent lipodystrophy. Most users find subcutaneous abdominal injections the most convenient option. Intranasal formulations were investigated in clinical trials (KP-102 LN) but showed lower and less reliable bioavailability than injectable routes.

Reconstitution, Storage & Prep

GHRP-2 is supplied as a lyophilized (freeze-dried) white powder requiring reconstitution before use.

Reconstitution Process:

  1. Allow the peptide vial to reach room temperature
  2. Using a sterile syringe, draw the desired volume of bacteriostatic water (typically 2.5 mL per 5 mg vial or 5 mL per 10 mg vial for convenient 1:1 dosing math)
  3. Inject the water slowly against the vial wall, letting it run down gently to avoid damaging the peptide
  4. Swirl gently until fully dissolved; never shake
  5. The solution should be clear and colorless

Dosing Calculation Example:

If reconstituting 5 mg with 2.5 mL bacteriostatic water, the concentration equals 2 mg/mL (2000 mcg/mL). For a 200 mcg dose, draw 0.1 mL (10 units on a standard U-100 insulin syringe).

Storage Guidelines:

  • Unreconstituted powder: Store frozen at -20 degrees C for long-term stability, or refrigerated at 2 to 8 degrees C for shorter periods; stable for 12 or more months when frozen
  • Reconstituted solution: Refrigerate at 2 to 8 degrees C (36 to 46 degrees F); use within 3 to 4 weeks for optimal potency
  • Never freeze reconstituted peptides, as freeze-thaw cycles degrade the molecular structure
  • Protect from light; keep vials in their original box or wrapped in foil
  • Use bacteriostatic water (not sterile water) for multi-dose vials to prevent bacterial contamination

Frequently Asked Questions

GHRP-2 generally produces higher peak GH release than GHRP-6 and causes less appetite stimulation, making it preferable when caloric intake must be controlled. GHRP-6 triggers stronger hunger due to greater ghrelin-like activity. Both raise cortisol and prolactin, but GHRP-2's elevations tend to be more moderate.

GHRP-2 produces stronger peak GH release but is less selective. Ipamorelin does not meaningfully raise cortisol, ACTH, or prolactin even at very high doses, whereas GHRP-2 causes moderate elevations in all three. Ipamorelin is chosen for cleanliness; GHRP-2 is chosen for raw GH output.

The most commonly cited dose is 100 to 300 mcg per injection administered subcutaneously, one to three times daily. A single 100 mcg dose at bedtime is a typical starting point, with users titrating upward based on response and tolerance.

Yes, but moderately. GHRP-2 activates ghrelin receptors and does increase food intake in clinical studies, though the effect is notably less intense than GHRP-6's strong hunger response. Users focused on body recomposition often prefer GHRP-2 or ipamorelin over GHRP-6 for this reason.

By peak GH output, GHRP-2 is generally considered the most potent of the traditional GHRPs (GHRP-1, GHRP-2, GHRP-6, hexarelin). A study by Arvat et al. (1997) showed GHRP-2 produced GH responses exceeding those of maximal-dose GHRH when administered intravenously. However, hexarelin is comparable in potency with a slightly different side effect profile.

GHRP-2 is used off-label in anti-aging protocols to restore more youthful GH pulsatility. Elevated GH and IGF-1 levels are associated with improved skin quality, body composition, sleep, and recovery. Long-term safety data for this specific application is limited, and it remains unapproved for this use.

GHRP-2 is administered via subcutaneous injection on an empty stomach, at least 30 minutes before eating or 2 or more hours after a meal. The pre-bed dose is considered most important because it amplifies the natural nocturnal GH surge. Elevated blood glucose and insulin blunt the GH response.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Arvat E, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6):885-891.
  2. Mericq V, et al. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. Journal of Clinical Endocrinology & Metabolism. 1998;83(7):2355-2360.
  3. Berlanga-Acosta J, et al. Synthetic growth hormone-releasing peptides (GHRPs): a historical appraisal of the evidences supporting their cytoprotective effects. Clinical Medicine Insights: Cardiology. 2017;11:1179546817694558.
  4. Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020;3(1):25-37.
  5. Laferrere B, et al. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. Journal of Clinical Endocrinology & Metabolism. 2005;90(2):611-614.
  6. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
  7. Pihoker C, et al. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature. Journal of Clinical Endocrinology & Metabolism. 1995;80(10):2987-2992.
  8. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D. Drugs in R&D. 2004;5(4):236-239.
  9. Chihara K, et al. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. Eur J Endocrinol. 2007;157(1):19-27.
  10. Thomas A, et al. Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by LC-MS/MS. Rapid Communications in Mass Spectrometry. 2010;24(11):1549-1557.
  11. World Anti-Doping Agency. The 2026 Prohibited List International Standard.
←Read the full GHRP-2 guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”